Massive Bio’s Co-Founder and CMO, Dr. Arturo Loaiza-Bonilla, to Speak at Precision Med Tri-Con 2024 in San Diego
Massive Bio is excited to announce that Co-Founder and Chief Medical Officer, Dr. Arturo Loaiza-Bonilla, will be participating as a panelist at the highly anticipated Precision Medicine Tri-Conference (Precision Med Tri-Con) taking place from March 26-28, 2024, in San Diego, California. Hosted at the Hilton San Diego Bayfront, this prestigious event is a key gathering in the field of precision medicine, bringing together leading experts and innovators to share the latest advancements, tackle challenges, and discuss the future direction of the sector.
Dr. Loaiza-Bonilla’s involvement highlights Massive Bio’s dedication to pioneering the integration of advanced technology and medical expertise to develop healthcare solutions that are tailored to the unique needs of individual patients. As a respected authority in precision medicine, Dr. Loaiza-Bonilla will lead a panel discussion on March 27, from 4:15-5:15 pm PT, focusing on the cutting-edge use of Artificial Intelligence (AI) and Large Language Models (LLMs) in enhancing patient-centric approaches within oncology.
Panel Discussion: “ Innovation in AI for Precision Oncology: Commercialization and Implementation Strategies”
This panel will delve into the transformative potential of AI and LLMs in precision oncology, from early detection and diagnosis to the personalization of treatment strategies. Dr. Loaiza-Bonilla, alongside esteemed panelists, will explore how these technologies are being employed to refine diagnostic accuracy, improve treatment outcomes, and facilitate more informed clinical decision-making, thus significantly advancing patient care in oncology. Attendees will gain invaluable insights into the innovative applications of AI in oncology, underscoring Massive Bio’s commitment to leveraging technology for the betterment of patient outcomes.
Participants of the Precision Med Tri-Con can anticipate an enriching agenda filled with informative sessions, interactive discussions, and networking opportunities. Dr. Loaiza-Bonilla will also share his experiences as an active clinician and research director at Capital Health Cancer Center, bringing valuable practical insights and a wealth of knowledge to the discussion.
For additional information about the Precision Med Tri-Con 2024, including travel arrangements and early registration, please visit the conference website at https://www.triconference.com/.
